Prevención integral del cáncer de cuello uterino

  1. José Antonio Vidart Aragón 1
  2. Javier Cortés 2
  1. 1 Real Academia Nacional de Medicina de España
  2. 2 Real Academia de Medicina de las Islas Baleares
Revista:
Anales de la Real Academia Nacional de Medicina

ISSN: 0034-0634

Año de publicación: 2019

Número: 136

Páginas: 287-291

Tipo: Artículo

DOI: 10.32440/AR.2019.136.03.REV09 DIALNET GOOGLE SCHOLAR lock_openAcceso abierto editor

Otras publicaciones en: Anales de la Real Academia Nacional de Medicina

Resumen

Se revisa la evidencia que sustenta la recomendación formulada por la Organización Mundial de la Salud orientada a la erradicación en el medio plazo del cáncer de cérvix a través de la aplicación sinérgica con altas coberturas de la vacunación frente al virus papiloma humano y del cribado rediseñado.

Referencias bibliográficas

  • Zur Hausen H, Meinhof W, Scheiber W, Bornkamm GW.: Attempts to detect virus-specific DNA in human tumors. I. Nucleic acid hybridizations with complementary RNA of human wart virus. Int J Cancer. 1974; 13: 650-656.
  • Zur Hausen H.:Human papillomaviruses in the pathogenesis of anogenital cancer. Virology 1991; 184(1): 9-13
  • Walboomers JM, Jacobs MV, Manos MM et al.: Human papillomavirus is a necessary cause of invasive cervical cancer worldwide. J Pathol. 1999; 189: 12-19.
  • Ghebreyesus TA.: WHO Meeting. Genève. 19 de Mayo 2018.
  • Peng S, Frazer IH, Fernando GJ, Zhou J.: Papillomavirus virus-like particles can deliver CTL epitopes to the MHC class I pathway. Virology. 1989; 240: 147-157.
  • Vacunas Profilácticas frente al Virus del Papiloma Humano: Documento de Consenso de las Sociedades Científicas Españolas. 31 de Enero de 2007. J. Cortés Coordinador. SP.MSD Ediciones.
  • https://www.mscbs.gob.es/profesionales/saludPublica/prevPromocion/vacunaciones/docs/CoberturasVacunacion/Tabla11.pdf Acceso 29 de Abril de 2019.
  • Departamentos Médicos de Merck y GlaxoSmithKline. Comunicación Personal.
  • Cortés J.: ¿Por qué no prescribes la vacuna VPH? En preparación.
  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/000721/WC500024634.pdf. Acceso 2 de Mayo 2019.
  • http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Summary_for_the_public/human/003852/WC500189114.pdf. Acceso 3 de Mayo 2019.
  • Pollock KG.: Sustained cross-protection of the bivalent HPV vaccine.J Infect Dis. 2018; 10: 1515-1516.
  • World Health Organization: Weekly Epidemiological Report. Human Papillomavirus vaccine: WHO Position Paper May 2017.; 82: 241-268.
  • Palmer T.: Prevalence of cervical disease at age 20 after immunisation with bivalent HPV vaccine at age 12-13 in Scotland: retrospective population study. Br Med J 2019; 365 doi: https://doi.org/10.1136/bmj.l1161
  • Sakamoto M, Miyagi E, Sumi Y et al.: Effectiveness on high-grade cervical abnormalities and long-term safety of the quadrivalent human papillomavirus vaccine in Japanese women. J Infect Chemother. 2019 : S1341-321X(18)30302-7. doi: 10.1016/j.jiac.2019.02.012.
  • Herweijer E, Sundström K, Ploner A, Uhnoo I, Sparén P, Arnheim-Dahlström L.: Quadrivalent HPV vaccine effectiveness against highgrade cervical lesions by age at vaccination: A population-based study. Int J Cancer. 2016; 138: 2867-2874.
  • Cortés J.: Vacunatión and fake-news. Salut i Força. 2019; 391: 3.
  • Cortés J.: Estrategias de cribado del cáncer de cuello uterino. Prog Obstet Ginecol 2005; 48 Supl 1: 228 – 230.
  • Georgalis L, de Sanjosé S, Esnaola M, Bosch FX, M Diaz M.: Present and future of cervical cancer prevention in Spain: a cost-effectiveness analysis. Eur J Cancer Prev. 2016; 25: 430-439.
  • Cortés J, Bosch FX, Concha A, et al.: Spanish Cancer Association: Cervical Cancer Prevention Position Statement. Prog Obstet Ginecol.2019; 61: 510 – 544.
  • Papanicolaou GN, Traut HF.: The diagnostic value of vaginal smears in carcinoma of the uterus. 1941. Arch Pathol Lab Med. 1997; 121: 211-214
  • Papanicolaou GN.: New Cancer Diagnosis. Third Race Betterment Conference. Battje Creek, Michigan, USA. 1928.
  • Christopherson WM, Parker JE, Drye JC.: Control of cervical cancer. Preliminary report on community program. JAMA. 1962; 182: 179-182.
  • Walton RJ.: Editorial: The task force on cervical cancer screening programs. Can Med Assoc J. 1976; 114(11): 981.
  • Cuzick J, Clavel C, Petry KU et al.: Overview of the European and North American studies on HPV testing in primary cervical cancer screening. Int J Cancer. 2006; 119: 1095-1101.
  • Mayrand MH, Duarte-Franco E, Rodrigues I et al.: Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer. N Engl J Med. 2007; 357: 1579-1588.
  • van der Horst J, Siebers AG, Bulten J, Massuger LF, de Kok IM.: Increasing incidence of invasive and in situ cervical adenocarcinoma in the Netherlands during 2004-2013. Cancer Med. 2017; 6: 416-423.
  • Ronco G, Dillner J, Elfström KM et al for the International HPV screening working group: Efficacy of HPV-based screening for prevention of invasive cervical cancer: follow-up of four European randomised controlled trials. Lancet. 2014; 383: 524-532.
  • Koliopoulos G, Nyaga VN, Santesso N et al.: Cytology versus HPV testing for cervical cancer screening in the general population. Cochrane Database Syst Rev. 2017; Aug 10;8: CD008587.
  • Quinn M, Babb P, Jones J, Allen E.: Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. Br Med J. 1999; 318: 904-908.
  • Torné A, del Pino M, Cusidó M et al.: Guía de cribado del cáncer de cuello de útero en España. Prog Obstet Ginecol. 2014; 57 (Supl.1): 1-53.
  • Ibáñez R, Alejo M, Combalia N et al.: Underscreened Women Remain Overrepresented in the Pool of Cervical Cancer Cases in Spain: A Need to Rethink the Screening Interventions. Biomed Res Int. 2015; vol.2015: Article ID 605375. 9 pages.
  • https://boe.es/boe/dias/2019/04/27/pdfs/BOEA-2019-6277.pdf Acceso 30 de Abril de 2019.
  • Meijer CJ, Berkhof J, Castle PE et al.: Guidelines for human papillomavirus DNA test requirements for primary cervical cancer screening in women 30 years and older. Int J Cancer. 2009; 124: 516-520.
  • Hall MT, Simms KT, Lew JB et al.: The projected timeframe until cervical cancer elimination in Australia: a modelling study. Lancet Public Health. 2019; 4: e19-e27.
Fuente de los datos: Dialnet